What is the core technology behind Islet Sciences?

The core technology focuses on the transplantation of encapsulated porcine (pig) islets to provide new insulin-producing cells for diabetic patients. This is supported by a proprietary alginate capsule for protection and a novel method for maturing viable porcine islets, alongside a diagnostic component that detects beta cell death through DNA methylation patterns.

How does the company validate its scientific claims?

Validation is primarily achieved through peer-reviewed publications and prestigious institutional backing. The deck cites a 2011 PNAS paper co-authored by board member Kevan Herold of Yale University and a 2006 BBRC study. It also references funding from the NIH, the Iacocca Foundation, and the Juvenile Diabetes Research Foundation (JDRF).

Who are the key people involved in the project?

The deck highlights a 'Renowned Scientific Advisory Board' led by Thomas J. Kindt, PhD (former Director at NIAID/NIH). Other members include Kevan Herold (Yale), Jerry Nadler (Eastern Virginia Medical School), Steven Paraskevas (McGill), and Christian Mende (UCSD). The presentation focuses on these advisors rather than the executive management team.

What evidence is provided for the treatment's efficacy?

Slide 6 presents a graph showing that a combination of LSF and Exendin-4 lowered blood glucose levels in NOD mice from approximately 400 mg/dL to under 200 mg/dL over a 25-week period. Additionally, Slide 7 shows that LSF treatment maintains higher 'Islet Equivalent' counts in piglet cultures compared to control groups.

Is there a clear path to market in this deck?

No. While the deck outlines a 'Path to a Cure' (Slide 3), it is a biological path rather than a commercial one. The presentation lacks a regulatory timeline (FDA phases), a manufacturing strategy, a competitive analysis of other diabetes treatments, or a breakdown of how the investment will be used to reach the clinic.

Islet Sciences Pitch Deck Teardown: A Deep Dive

Islet Sciences’ May 2016 investor presentation is a science-heavy deck focused on a three-pronged path to curing diabetes: early diagnosis, prevention, and treatment via porcine islet transplantation. The company relies heavily on the pedigree of its Scientific Advisory Board, including members from Yale and McGill, to anchor its technical claims. The deck excels at showcasing peer-reviewed validation, citing PNAS and BBRC publications and NIH-funded studies from 2014. However, the provided slides lack a clear business model, market sizing, or a specific financial ask. It functions more as a…

Key takeaways

The Scientific Advisory Board chair, Thomas J. Kindt, managed a $340 million budget and 1,300 staff at the NIH (Slide 2).
The company’s strategy involves three pillars: early diagnosis of dying beta cells, prevention via immunological protection, and treatment through porcine islet transplantation (Slide 3).
Technical validation is provided by a 2011 PNAS publication regarding the detection of beta cell death using differentially methylated DNA (Slide 5).
Pre-clinical data shows that LSF in combination with Exendin-4 reverses T1DM in NOD mice, supported by a $250,000 Iacocca Foundation grant (Slide 6).
A 2014 NIH-funded study demonstrated that 50um LSF significantly improves islet recovery in piglet co-cultures over 48 hours (Slide 7).
The company claims an 'improved method' for pig islet isolation and maturation compared to previous porcine islet techniques (Slide 8).
The deck omits standard commercial slides such as market size (TAM/SAM/SOM), competitive landscape, and the specific funding amount requested.

Executive Summary: The Academic Heavyweight Approach

The Islet Sciences presentation from May 2016 is a quintessential example of a 'science-first' biotech deck. Rather than leading with market opportunity or financial projections, the company leads with the pedigree of its advisors and the depth of its peer-reviewed research. The central thesis is that diabetes can be treated, and potentially cured, by a combination of early DNA-based diagnosis and the transplantation of protected piglet islets. While the technical evidence is robust, the deck leaves significant gaps regarding the business execution and the competitive landscape of the diabetes market.

Slide 1: Title and Positioning

The cover slide introduces the company name, Islet Sciences, and the tagline 'Changing the way diabetes is treated.' The date, May 2016, places this deck in a period where regenerative medicine and islet transplantation were seeing significant academic interest. The logo, featuring three interlocking rings in blue, red, and silver, suggests a synergy between their three core pillars: diagnosis, prevention, and treatment.

Slide 2: The Scientific Advisory Board (SAB)

This is arguably the strongest slide in the deck. In early-stage biotech, the team is the primary asset. Islet Sciences highlights Thomas J. Kindt, PhD , as the Chair. The slide notes his massive scale of experience: managing a $340 Million budget and 1,300 staff members at the NIAID/NIH. By listing professors from Yale, McGill, and UCSD, the company is signaling to investors that their technology has passed the 'smell test' of the world's leading immunologists and transplant surgeons. The level of detail provided for Dr. Kindt—including his cum laude chemistry degree—is intended to build an impenetrable wall of credibility.

Slide 3: The Path to a Cure

Slide 3 outlines the company's three-pronged strategy. Early diagnosis is achieved by detecting damaged beta cells. Prevention involves protecting existing insulin-producing cells from immunological attack. Treatment is the most ambitious, involving the transplantation of encapsulated porcine islets and the regeneration of the patient's own cells. The slide includes three microscopic images: one showing the 'Islet Sciences alginate capsule,' another showing 'viable porcine islets,' and a third showing a 'Human islet protected by Lysofilline.' This slide effectively bridges the gap between high-level strategy and physical product.

Slide 4 & 5: Diagnostic Validation via DNA Detection

These slides focus on the 'Early Diagnosis' pillar. Slide 4 shows four charts (A through D) demonstrating that beta cell DNA is detectable in primary islets and murine cells. Chart A specifically shows a high 'Normalized ratio' for islets compared to kidney, liver, and brain tissue. Slide 5 reinforces this by displaying a full PNAS (Proceedings of the National Academy of Sciences) paper title: 'Detection of b cell death in diabetes using differentially methylated circulating DNA.' By featuring Kevan Herold, MD, PhD of Yale University prominently alongside the Yale logo, the deck leverages institutional prestige to validate the diagnostic side of the business.

Slide 6: Pre-clinical Efficacy in Mice

Slide 6 moves into the 'Treatment' pillar, showing a longitudinal study of blood glucose levels in NOD (Non-Obese Diabetic) mice. The data indicates that 'LSF' (Lysofilline) in combination with 'Exendin-4' successfully reversed Type 1 Diabetes Mellitus (T1DM). The graph shows blood glucose dropping significantly after implantation and remaining stable through week 25. Crucially, the slide mentions a new grant for $250,000 from the Iacocca Foundation to move this research into the clinic, providing evidence of non-dilutive funding and external validation.

Slide 7: NIH-Funded Piglet Islet Study

This slide focuses on the 2014 NIH-funded study regarding islet recovery. The data shows that islets cultured with 50um LSF maintained a higher 'Islet Equivalent' (above 600.00) over 48 hours compared to the control and 10um LSF groups, which saw sharp declines. This provides a specific dose-response justification for their treatment protocol. The mention of NIH funding again serves to de-risk the technology in the eyes of an investor.

Slide 8: Process Improvement

Slide 8 uses a 'Before vs. After' visual to show the 'Improved method of pig islet isolation and maturation.' The 'Previous Porcine Islet' image shows a fragmented, less defined cell cluster, while the 'Islet Sciences Piglet Islet' appears as a dense, spherical, and healthy-looking mass. The slide attributes this advancement to research from UC, NIH, and JGRF in 2014 . This slide is critical for the 'moat' argument—it suggests the company has a proprietary or superior way of preparing the biological material required for transplantation.

Slide 9: Conclusion

The final slide is a simple 'Thank you for your attention!' with the company logo and tagline. It lacks a 'Call to Action' or contact information, which is a missed opportunity for a pitch deck intended for distribution.

What Works in This Deck

Institutional Validation: The constant referencing of the NIH, PNAS, Yale, and McGill creates a sense of scientific inevitability. · Clear Strategic Pillars: The 'Path to a Cure' slide (Slide 3) provides a simple framework for understanding a very complex biological process. · Data-Driven: The inclusion of specific charts from peer-reviewed studies (Slides 4, 6, and 7) moves the deck beyond marketing fluff into hard evidence. · Advisory Pedigree: The detailed breakdown of the SAB's accomplishments (Slide 2) is excellent for a biotech firm where the 'who' is as important as the 'what.'

What Is Missing

Executive Management: While the advisors are world-class, the deck does not show who is actually running the company day-to-day (CEO, COO, CFO). · Market Opportunity: There is no mention of the number of T1DM patients, the cost of current treatments, or the potential pricing for an islet transplant. · Competitive Landscape: The deck does not address other companies working on islet encapsulation (e.g., ViaCyte) or other curative paths like CRISPR or stem cell therapy. · The Ask: There is no slide stating how much money the company is raising, what the valuation is, or what specific milestones the funding will achieve. · Regulatory Roadmap: For a biotech company in 2016, investors would expect to see a timeline for IND (Investigational New Drug) filing and Phase I/II clinical trials.

Founder Takeaways: Copy the Validation, Add the Business

Founders in deep tech or biotech should emulate the way Islet Sciences uses peer-reviewed data and institutional logos to build trust. If you have NIH funding or a PNAS paper, it should be front and center. However, avoid the mistake of making a 'science poster' instead of a 'business deck.' A successful fundraising presentation must bridge the gap between 'this works in mice' and 'this is a billion-dollar company.' Ensure you include a clear Go-To-Market (GTM) strategy , a regulatory timeline , and a specific financial ask to turn a scientific lecture into a compelling investment opportunity.

Frequently asked questions

What is the core technology behind Islet Sciences?: The core technology focuses on the transplantation of encapsulated porcine (pig) islets to provide new insulin-producing cells for diabetic patients. This is supported by a proprietary alginate capsule for protection and a novel method for maturing viable porcine islets, alongside a diagnostic component that detects beta cell death through DNA methylation patterns.
How does the company validate its scientific claims?: Validation is primarily achieved through peer-reviewed publications and prestigious institutional backing. The deck cites a 2011 PNAS paper co-authored by board member Kevan Herold of Yale University and a 2006 BBRC study. It also references funding from the NIH, the Iacocca Foundation, and the Juvenile Diabetes Research Foundation (JDRF).
Who are the key people involved in the project?: The deck highlights a 'Renowned Scientific Advisory Board' led by Thomas J. Kindt, PhD (former Director at NIAID/NIH). Other members include Kevan Herold (Yale), Jerry Nadler (Eastern Virginia Medical School), Steven Paraskevas (McGill), and Christian Mende (UCSD). The presentation focuses on these advisors rather than the executive management team.
What evidence is provided for the treatment's efficacy?: Slide 6 presents a graph showing that a combination of LSF and Exendin-4 lowered blood glucose levels in NOD mice from approximately 400 mg/dL to under 200 mg/dL over a 25-week period. Additionally, Slide 7 shows that LSF treatment maintains higher 'Islet Equivalent' counts in piglet cultures compared to control groups.
Is there a clear path to market in this deck?: No. While the deck outlines a 'Path to a Cure' (Slide 3), it is a biological path rather than a commercial one. The presentation lacks a regulatory timeline (FDA phases), a manufacturing strategy, a competitive analysis of other diabetes treatments, or a breakdown of how the investment will be used to reach the clinic.